SK Biopharmaceuticals gets marketing approval for epilepsy drug in Israel

The S.Korean pharmaceutical company plans to expand Cenobamate into West Asian markets

SK Biopharmaceuticals gets marketing approval for epilepsy drug in Israel
Yoo-Rim Kim 1
2023-05-03 18:06:39 youfrest@hankyung.com
Bio & Pharma

South Korea’s SK Biopharmaceuticals said on Wednesday that the Israeli Ministry of Health has approved the company's new drug application (NDA) for its epilepsy medication Cenobamate (local name Ecopri) on April 30. 

The application was submitted by Dexcel Pharma, the Israeli partner of SK Biopharmaceuticals. The approved drug includes a total of six dosages: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamate, an independently developed epilepsy drug by SK Biopharmaceuticals, was recognized for its efficacy in treating partial-onset seizures in adults and received marketing approval from the US Food and Drug Administration (FDA) in November 2019.

Following the recent approval, SK Biopharmaceuticals stated plans to accelerate its market strategy in Western Asia, including Israel.

Write to Yoo-Rim Kim at youfrest@hankyung.com
#SK Biopharmaceuticals #epilepsy drug #Cenobamate #Israel #marketing approval #FDA

SK Biopharm holds sales meeting for marketing Cenobamate in US

SK Biopharm holds sales meeting for marketing Cenobamate in US

SK Biopharm's sales meeting in San Diego  On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The purpose of the event is to motivate sales organizations and share future visions among US pharmaceuti

SK Biopharmaceuticals launches epilepsy drug in France

SK Biopharmaceuticals launches epilepsy drug in France

SK Biopharm's Cenobamate South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company launched the same drug in 15 European countries, beginning with Germany in June this year. The local drug brand name is "On

SK Biopharma's epilepsy treatment posts impressive growth in US

SK Biopharma's epilepsy treatment posts impressive growth in US

SK Biopharm researchers South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medication's sales in the first three quarters hit 119.4 billion won ($89 million), with the third quarter alone seeing growth o

SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

SK Biopharm researchers South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil’s Eurofarma Laboratórios S.A. to enter the Latin American market.With the technology transfer, SK aims to sell

SK Biopharm releases epilepsy treatment in UK

SK Biopharm releases epilepsy treatment in UK

SK Biopharm's Cenobamate, sold under the Xcopri brand in the US South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europe.The UK is the fourth country in Europe for SK to sell the drug, which is availabl
(* comment hide *}